PURE Bioscience (PURE) Regains Compliance With Nasdaq Listing Requirements
9/24/2012 9:17:11 AM
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has regained compliance with Nasdaq listing requirements, and will continue trading on the Nasdaq Capital Market. On September 21, 2012, the Company received a letter from the Nasdaq Listing Qualifications Staff stating PURE Bioscience, Inc. has regained compliance with the applicable minimum shareholders’ equity rule, as required by the Nasdaq Hearings Panel’s decision dated June 21, 2012, as modified on August 10, 2012 and September 11, 2012. The Staff also concluded that the Company is in compliance with all other applicable requirements set forth in such decision and required for listing on The Nasdaq Capital Market. Accordingly, the Nasdaq Hearings Panel has determined to continue the listing of the Company’s securities on The Nasdaq Stock Market and has closed this matter.
comments powered by